Mind Medicine (MNMD) Price & Analysis

Compare

1,946 Followers

MNMD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.70 - $12.76

Previous CloseN/A

Volume779.86K

Average Volume (3M)1.54M

Market Cap

$929.79M

Enterprise Value$412.10M

Total Cash (Recent Filing)$182.99M

Total Debt (Recent Filing)$41.19M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Nov 12, 2025

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding76,087,944

10 Day Avg. Volume2,245,285

30 Day Avg. Volume1,535,757

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)2.03

Price to Sales (P/S)0.00

P/FCF Ratio-6.20

Enterprise Value/Market Cap0.44

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-3.74

Forecast

1Y Price Target

$26.00

Price Target Upside107.01% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Drug InnovationMindMed continues to frame MM120’s clinical value proposition around infrequent, durable dosing, differentiating the drug from chronic daily therapies.

Financial HealthMindMed has a robust cash position of $237.9 million, supporting its ongoing development efforts.

Strategic PositionBreakthrough Therapy designation granted by the FDA to MM120 in GAD supports the company's strategic position.

Bears Say

Trial DependencyThe company’s stock movement is heavily dependent on the successful results of its pivotal trials expected in 2026.

Mind Medicine News

Psychedelic: Exclusive talk with ibogaine clinic Beond

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Tom Feegel, CEO and co-founder of...

9d ago

ATAI

CMND

Mind Medicine participates in a conference call with Cantor Fitzgerald

Conference call with management will be held on September 29 at 12 pm hosted by Cantor Fitzgerald.Webcast Link...

12d ago

MNMD

Psychedelic: Exclusive talk with biopharma company MindMed

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Daniel Karlin, Chief Medical Officer at...

16d ago

MNMD

MindMed Study Highlights Urgent Need for Suicide Risk Screening in GAD Patients

Mind Medicine ( ($MNMD) ) has issued an announcement. MindMed presented a study at Psych Congress 2025 revealing...

11d ago

MNMD

MindMed Issues Inducement Grants to New Employees

Mind Medicine ( ($MNMD) ) has shared an update. MindMed has announced the issuance of inducement grants to...

11d ago

MNMD

Mind Medicine’s Strategic Focus and Commercial Scalability Drive Buy Rating

In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Mind Medicine, with...

22d ago

MNMD

MindMed to Engage in Key September Investor Conferences

Mind Medicine ( ($MNMD) ) just unveiled an update. MindMed has announced its participation in several investor conferences...

25d ago

MNMD

MindMed’s MM120 Shows Promise in Treating Generalized Anxiety Disorder

An update from Mind Medicine ( ($MNMD) ) is now available. Mind Medicine announced that the Journal of...

25d ago

MNMD

MindMed Issues Inducement Grants to New Employees

Mind Medicine ( ($MNMD) ) has shared an update. MindMed announced the issuance of inducement grants to five...

25d ago

MNMD

MindMed Issues Inducement Grants to New Employees

Mind Medicine ( ($MNMD) ) has provided an update. MindMed announced the issuance of inducement grants to five...

25d ago

MNMD

Mind Medicine’s Breakthrough in Anxiety Disorder Treatment

Mind Medicine ( ($MNMD) ) has shared an announcement. On September 4, 2025, Mind Medicine announced the publication...

1M ago

MNMD

Mind Medicine announces publication of results from MM120 Phase 2b study

Mind Medicine (MNMD) announced that JAMA has published full results from the Company’s Phase 2b study of MM120...

1M ago

MNMD

MindMed Reports Strong Phase 3 Trial Progress and Leadership Appointment

Mind Medicine ( ($MNMD) ) has provided an announcement. MindMed has reported strong enrollment in its three Phase...

2M ago

MNMD

MindMed to Announce Q2 2025 Financial Results in Upcoming Webcast

The latest update is out from Mind Medicine ( ($MNMD) ). MindMed announced it will host a live...

2M ago

MNMD

MNMD FAQ

What was Mind Medicine’s price range in the past 12 months?

Mind Medicine lowest stock price was $4.70 and its highest was $12.76 in the past 12 months.

What is Mind Medicine’s market cap?

Mind Medicine’s market cap is $929.79M.

When is Mind Medicine’s upcoming earnings report date?

Mind Medicine’s upcoming earnings report date is Nov 12, 2025 which is in 39 days.

How were Mind Medicine’s earnings last quarter?

Mind Medicine released its earnings results on Aug 05, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.12.

Is Mind Medicine overvalued?

According to Wall Street analysts Mind Medicine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mind Medicine pay dividends?

Mind Medicine does not currently pay dividends.

What is Mind Medicine’s EPS estimate?

Mind Medicine’s EPS estimate is -0.5.

How many shares outstanding does Mind Medicine have?

Mind Medicine has 76,087,944 shares outstanding.

What happened to Mind Medicine’s price movement after its last earnings report?

Mind Medicine reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 2.593%.

Which hedge fund is a major shareholder of Mind Medicine?

Currently, no hedge funds are holding shares in MNMD

Mind Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-59.11%

Trailing 12-Months

Asset Growth

-1.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mind Medicine

Mind Medicine (MNMD), also known as MindMed, is a biotechnology company focused on developing psychedelic-inspired therapies for the treatment of mental health disorders. The company operates in the biopharmaceutical sector, primarily targeting conditions such as anxiety, depression, addiction, and ADHD through innovative drug development. MindMed's core products and services include research and development of novel psychedelic compounds, clinical trials, and collaborations with healthcare professionals to create effective mental health treatments.

Mind Medicine (MNMD) Earnings & Revenues

Historic Earnings Reports

MNMD Company Deck

MNMD Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook for MindMed, driven by strong enrollment in pivotal trials, financial stability, and strategic leadership additions. However, increased R&D expenses present a financial challenge, although they are aligned with the company's growth and trial activities.View all MNMD earnings summaries

MNMD Stock 12 Month Forecast

Average Price Target

$26.00

▲(107.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","17":"$17","30":"$30","43":"$43","56":"$56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17,30,43,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.13,12.65846153846154,16.186923076923076,19.715384615384615,23.243846153846153,26.77230769230769,30.300769230769227,33.82923076923077,37.357692307692304,40.886153846153846,44.41461538461538,47.94307692307692,51.47153846153846,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.13,10.427692307692308,11.725384615384616,13.023076923076923,14.32076923076923,15.618461538461538,16.916153846153847,18.213846153846156,19.51153846153846,20.809230769230766,22.106923076923074,23.404615384615383,24.70230769230769,{"y":26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.13,9.65846153846154,10.186923076923078,10.715384615384616,11.243846153846155,11.772307692307693,12.30076923076923,12.829230769230769,13.357692307692307,13.886153846153846,14.414615384615384,14.943076923076923,15.471538461538461,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >